NCT07630155 Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
| NCT ID | NCT07630155 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan Rogel Cancer Center |
| Condition | Renal Pelvis and Ureter Urothelial Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-08 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-08 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged ≥ 18 year. Both sexes are included to reflect the patient population with upper tract urothelial carcinoma (UTUC) already being followed at the University of Michigan and allow exploration of potential differences in tolerability of awake ureteroscopy based on sex * History of endoscopically managed UTUC at any time, or a suspected diagnosis of UTUC based on pre-procedure imaging, and is already planned for office-based ureteroscopic assessment * Ability and willingness to complete and adhere to survey questions and responses throughout study duration Exclusion Criteria: * Known ureteral strictures * Active urinary tract infection * Need for general anesthesia due to patient or procedural factors * History of inability to tolerate ureteroscopy under local anesthetic * Anticipated need for laser ablation during the surveillance procedure * Pregnancy
Contact & Investigator
Khurshid Ghani, MD
PRINCIPAL INVESTIGATOR
University of Michigan Rogel Cancer Center
Frequently Asked Questions
Who can join the NCT07630155 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Pelvis and Ureter Urothelial Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07630155 currently recruiting?
Yes, NCT07630155 is actively recruiting participants. Contact the research team at Uymichae@med.umich.edu for enrollment information.
Where is the NCT07630155 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07630155 clinical trial?
NCT07630155 is sponsored by University of Michigan Rogel Cancer Center. The principal investigator is Khurshid Ghani, MD at University of Michigan Rogel Cancer Center. The trial plans to enroll 10 participants.